Impact of Lipoabdominoplasty and Rectus Diastasis Repair on Benzodiazepine Usage in Patients with Depression and Anxiety: A Prospective Study.

Abstract

Lipoabdominoplasty, primarily sought for cosmetic enhancement, has shown potential benefits beyond physical transformation. Emerging evidence suggests that aesthetic procedures may positively affect mental health by improving body image and self-esteem. This study aims to assess the impact of lipoabdominoplasty on pharmacologic therapy (ie, benzodiazepines) use in patients with preexisting depression or anxiety disorders. This prospective cohort study included 69 patients who underwent lipoabdominoplasty. All patients were taking benzodiazepines before surgery, with dosage frequency recorded. Follow-up assessments were conducted postoperatively to document changes in drug use and evaluate mental health improvements using validated scales, including the BODY-Q. A significant reduction in benzodiazepine use was observed postoperatively. At follow-up, 17% of patients discontinued medication, and 61% required a lower dosage ( P < 0.05). Complications occurred in 16% of cases, including seroma ( n = 6), infection ( n = 2), hematoma ( n = 2), and necrosis ( n = 1); 1 patient required reintervention. BODY-Q scores demonstrated significant improvements in body image and self-esteem. Lipoabdominoplasty may contribute to reduced drug use, likely driven by improvements in body image and psychologic well-being. These findings underscore the potential of aesthetic surgery to enhance mental health in patients with depression or anxiety, offering an integrated holistic care approach. Therapeutic, IV.